Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Rodrigues, Loreta M ^a   Chung, Yuen Li ^b   Al Saffar, Nada M S ^b   Sharp, Swee Y ^c   Jackson, Laura E ^b   Banerji, Udai ^c   Stubbs, Marion ^a   Leach, Martin O ^b   Griffiths, John R ^a   Workman, Paul ^c  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

17 AAG; ERBB2 HER2 NEU; HSP90; Magnetic resonance spectroscopy; MMTV NEU NT tumours

Indexed keywords

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS;

BENZOQUINONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; TANESPIMYCIN; TUMOR MARKER;

ANIMAL; ARTICLE; CELL CULTURE; CELL SEPARATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; METABOLISM; METHODOLOGY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; TRANSGENIC MOUSE; TUMOR VOLUME;

ANIMALS; BENZOQUINONES; CELL SEPARATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; MAGNETIC RESONANCE SPECTROSCOPY; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; RECEPTOR, ERBB-2; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84861332405     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-250     Document Type: Article

References (45)

1. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A Phase I dose-escalation study. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA, J Clin Oncol 2007 25 5410 5417 10.1200/JCO.2007.11.7960 18048823 (Pubitemid 350232217)
2. HSP90 Inhibition is Effective in Breast Cancer: A Phase 2 Trial of Tanespimycin (17AAG) plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Modi S, Stopeck AT, Linden HM, Solit DB, Chandarlapaty S, Rosen N, DAndrea G, Dickler MN, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C, Clin Cancer Res 2011 17 5132 5139 10.1158/1078-0432.CCR-11-0072 21558407
3. Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer? Arteaga CL, Clin Cancer Res 2011 17 4919 4921 10.1158/1078-0432.CCR-11- 1218 21670086
4. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Slamon DJ, Clarke GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, Science 1987 235 177 182 10.1126/science.3798106 3798106 (Pubitemid 17231334)
5. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M, Oncologist 2006 11 318 324 10.1634/theoncologist.11-4-318 16614227
6. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KM, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aheme W, McDonald E, Workman P, Cancer Res 2007 67 2206 2216 10.1158/0008-5472.CAN-06-3473 17332351 (Pubitemid 46424240)
7. HSP90 molecular chaperone inhibitors: are we there yet? Neckers L, Workman P, Clin Cancer Res 2012 18 1 64 76 10.1158/1078-0432.CCR-11-1000 22215907
8. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that over express HER2. Basso A, Solit D, Munster P, Rosen N, Oncogene 2002 21 1159 1166 10.1038/sj.onc.1205184 11850835 (Pubitemid 34185232)
9. The HSP90 molecular chaperone: an open and shut case for treatment. Pearl LH, Prodromou C, Workman P, Biochem J 2008 410 439 453 10.1042/BJ20071640 18290764 (Pubitemid 351429015)
10. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Workman P, Maloney A, Expert Opin Biol Ther 2002 2 3 24 10.1517/14712598.2.1.3 11772336 (Pubitemid 34462457)
11. HSP90 inhibition: two-pronged exploitation of cancer dependencies. Travers J, Sharp S, Workman P, Drug Discov Today 2012 17 5-6 242 252 Epub 2011 Dec 30 10.1016/j.drudis.2011.12.021 22245656
12. Drugging the cancer chaperone HSP90. Workman P, Burrows F, Neckers L, Rosen N, Ann N Y Acad Sci 2007 1113 202 216 10.1196/annals.1391.012 17513464 (Pubitemid 350015011)
13. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ, Nature 2003 425 357 359 10.1038/425357a 14508471 (Pubitemid 37187252)
14. HSP90 and the chaperoning of cancer. Whitesell L, Lindquist S, Nat Rev Cancer 2005 5 761 772 10.1038/nrc1716 16175177 (Pubitemid 41400776)
15. Insights from transgenic mouse models of ERBB2-induced breast cancer. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ, Nat Rev Cancer 2007 7 389 397 10.1038/nrc2127 17446858 (Pubitemid 46652484)
16. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P, Cell 1988 54 105 115 2898299
17. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. Workman P, Aboagye EO, Chung Y-L, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, Zweit J, J Natl Cancer Inst 2006 98 580 598 10.1093/jnci/djj162 16670384 (Pubitemid 43904842)
18. Early tumour response to Hsp90 therapy using HER2 PET: comparison with 18F- FDG PET. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson M, J Nucl Med 2006 47 793 796 16644749 (Pubitemid 46768442)
19. Molecular imaging in drug development. Wilmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS, Nat Rev Drug Discov 2008 7 591 607 10.1038/nrd2290 18591980 (Pubitemid 351927724)
20. Applications of magnetic resonance in model systems. Tumour Biology and Physiology. Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M, Robinson SP, Sotak CH, Van Der Sanden B, Neoplasia 2000 2 139 151 10.1038/sj.neo.7900076 10933073 (Pubitemid 30123185)
21. Applications of magnetic resonance in model systems: Cancer Therapeutics. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, Swartz HM, Neoplasia 2000 2 152 165 10.1038/sj.neo.7900078 10933074 (Pubitemid 30123186)
22. The C-neu mammary carcinoma in oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. Rodrigues LM, Stubbs M, Robinson SP, Newell B, Mansi J, Griffiths JR, MAGMA 2004 17 260 270 10.1007/s10334-004-0070-8 15703983 (Pubitemid 40362309)
23. 31P measurements of response to treatment. Leach MO, Verrill M, Glaholm J, Smith TA, Colins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, Smith IE, NMR Biomed 1998 11 314 340 10.1002/(SICI)1099-1492(1998110) 11:7<314::AID-NBM522>3.0.CO;2-Z 9859939 (Pubitemid 28547368)
24. Magnetic resonance spectroscopy of cancer-practicalities of multi-cancer trials and early results in non-Hodgkins lymphoma. Griffiths JR, Tate AR, Howe FA, Stubbs M, Eur J Cancer 2002 38 2085 2093 10.1016/S0959-8049(02)00389-1 12387834 (Pubitemid 35223246)
25. Using metabolomics to monitor anticancer drugs. Chung YL, Griffiths JR, Ernst Schering Found Symp Proc 2007 4 55 78 18811053
26. Magnetic Resonance Spectroscopic Pharmacodynamic markers of Hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG) in human colon cancer models. Chung Y-L, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM, J Natl Cancer Inst 2003 95 1624 1633 10.1093/jnci/djg084 14600095 (Pubitemid 37455930)
27. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Brandes AH, Ward CS, Ronen SM, Breast Cancer Res 2010 12 84 10.1186/bcr2729 20946630
28. Proton MRS detects Metabolic Changes in Hormone Sensitive and Resistant Human Prostate Cancer Model CWR22 and CWR22r. Le Carl H, Lupu M, Kotedia K, Rosen N, Solit D, Koutcher JA, Magn Reson Med 2009 62 5 1112 1119 10.1002/mrm.22137 19780165
29. UKCCCR Guidelines for the welfare of animals in experimental neoplasia. Workman P, et al. Br J Cancer 1998 77 1 1 10 9665378
30. Image selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. Ordidge RJ, Connelly A, Lohman JAB, J Magn Reson 1986 66 283 294 10.1016/0022-2364(86)90031-4
31. 31P NMR signals using the variable projection method and prior knowledge. Van der Veen JWC, de Beer R, Luyten PR, van Ormondt D, Magn Reson Med 1988 6 92 98 10.1002/mrm.1910060111 3352510 (Pubitemid 18057210)
32. Establishment of an isogenic human colon tumour model for NQO1 gene expression: Application to investigate the role of DT- diaphorase in bioreductive drug activation in vitro and in vivo. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P, Mol Pharmacol 2000 58 1146 1155 11040064
33. Flow Cytometric Detection of Apoptosis: Comparison of the Assays of In Situ DNA Degradation and Chromatin Changes. Hotz MA, Gong J, Traganos F, Darzynkiewicz Z, Cytometry 1994 15 237 244 10.1002/cyto.990150309 8187583
34. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Al-Saffar NMS, Troy H, RamirezdeMolina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL, Cancer Res 2006 66 1 427 434 10.1158/0008-5472.CAN-05-1338 16397258 (Pubitemid 43166051)
35. Simultaneous extraction of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy. Tyagi RK, Azrad A, Degani H, Salomon Y, Magn Reson Med 1996 35 194 200 10.1002/mrm.1910350210 8622583 (Pubitemid 26044386)
36. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G, Matthews TP, Cheung KM, Kalusa A, James K, Hayes A, Hardcastle A, Dymock B, Brough PA, Barril X, Cansfield JE, Wright L, Surgenor A, Foloppe N, Hubbard RE, Aherne W, Pearl L, Jones K, McDonald E, Raynaud F, Eccles S, Drysdale M, Workman P, Mol Cancer Ther 2007 6 4 1198 1211 10.1158/1535-7163.MCT-07-0149 17431102 (Pubitemid 46711983)
37. Phase I pharmacokinetic and pharmacodynamic study of 17-Allylamino, 17-Demethoxygeldanamycin in patients with advanced malignancies. Banerji U, ODonnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I, J Clin Oncol 2005 23 4152 4161 10.1200/JCO.2005.00.612 15961763 (Pubitemid 46211321)
38. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino,17-demethoxygeldanamycin in human ovarian cancer xenograft models. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P, Clin Cancer Res 2005 11 7023 7032 10.1158/1078-0432.CCR-05-0518 16203796 (Pubitemid 41428762)
39. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Eaton JD, Perry MJA, Todryk SM, Mazucco RA, Kirby RS, Griffiths JR, Dalgleish AG, Gene Ther 2001 8 557 567 10.1038/sj.gt.3301432 11319623 (Pubitemid 32409531)
40. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demthoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Clarke PA, Hostein I, Banerji U, Di Stefano F, Maloney A, Walton M, Judson I, Workman P, Oncogene 2000 19 4125 4133 10.1038/sj.onc.1203753 10962573
41. Studies of human tumours by MRS: a review. Negendank W, NMR Biomed 1992 5 303 324 10.1002/nbm.1940050518 1333263
42. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, Leach MO, Oncotarget 2010 1 3 185 197 21037799
43. The mighty mouse: genetically engineered mouse models in cancer drug development. Sharpless NE, DePinho RA, Nat Rev Drug Discov 2006 5 741 754 10.1038/nrd2110 16915232 (Pubitemid 44323701)
44. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Olive K, Tuveson D, Clin Cancer Res 2006 12 5277 5287 10.1158/1078-0432.CCR-06-0436 17000660 (Pubitemid 44497240)
45. Differences in vascular response between primary and transplanted tumours. Field SB, Needham S, Burney IA, Maxwell RJ, Coggle JE, Griffiths JR, Br J Cancer 1991 63 723 726 10.1038/bjc.1991.163 1645562